ClinicalTrials.gg
AvailableNCT07422389Updated Feb 20, 2026

BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

An expanded access record providing BRM421 Ophthalmic Solution, 0.06% in Limbal Stem Cell Deficiency (LSCD), sponsored by BRIM Biotechnology Inc.. Available at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by BRIM Biotechnology Inc. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops.

Participants will:

  • Use BRM421 two times a day for at least 12 weeks
  • Visit the clinic monthly for checkups and tests
02

Conditions studied

  • Limbal Stem Cell Deficiency (LSCD)
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

BRIM Biotechnology Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with mild to moderate LSCD who unsatisfied with the standard of care treatments and who seek the treatment with BRM421 Ophthalmic Solution. Patients scheduled for LSC transplant may be included, but treatment with BRM421 should begin only after the surgery.
  • Be able to sign the and follow with investigator instructions.
  • If a female is of , they must: use an acceptable means of (acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives, mechanical spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner) and have a negative urine pregnancy test at the time of consent.

Exclusion criteria

Exclusion Criteria:

  • The patients eligible for the BRIM clinical trial(s).
  • The patients diagnosed with primary LSCD which is the genetic mutations that lead to LSC dysfunction or destruction.
  • Have a condition or a situation in which the investigator feels the patients is not suitable and may put the patient at significant risk.
  • Be a female who is pregnant, nursing, or planning a pregnancy at the time of consent. Be a woman of who is not using an acceptable means of ; acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives; mechanical spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. The risks of BRM421 among pregnant patients are not known.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • DrugFulipiftideStudies of FulipiftideFulipiftide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.

06

Where to request access

1 of 1 sites recruiting
  • Scheie Eye Institute
    Philadelphia, Pennsylvania 19104, United States
    Available
    • Bennie Jeng, MD · Contact
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07422389
Lead sponsor
BRIM Biotechnology Inc.
Responsible party
Sponsor
First posted
Feb 20, 2026
Last update
Feb 20, 2026

Study contacts

Emma Iacobucci
Contact
emma.iacobucci@pennmedicine.upenn.edu
215-662-9393
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion